Alkermes plc: Alkermes Publishes Investor Presentation Detailing Company's Transformation and Value Creation

Strategic, Operational and Governance Enhancements Have Driven Strong Stock Price Performance and TSR Outperformance in Comparison to Peers Reiterates Board's Belief that Sarissa Nominees

Related Keywords

Delaware ,United States ,Athlone ,Westmeath ,Ireland ,Ohio ,Zeiten ,Mecklenburg Vorpommern ,Germany ,Massachusetts ,Waltham ,Innisfree ,Sligo ,Dublin ,Canada ,Catot Laurencin ,Emily Peterson Alva ,Chris Kittredge Zachary Tramonti ,Katie Joyce ,Christopheri Wright ,Sandy Coombs ,Alexander Denner ,Richardb Gaynor ,Shanem Cooke ,Brianp Mckeon ,Stefan Klotter ,Emergent Biosolutions Inc ,Johnson ,Jazz Pharmaceuticals ,Acadia Pharmaceuticals Inc ,Neurocrine Biosciences Inc ,Corporate Governance Committee ,Governance Committee ,Therapeutics Inc ,Company Board Of Directors The ,Sage Therapeutics Inc ,Ultragenyx Pharmaceutical Inc ,Sarepta Therapeutics Inc ,Ironwood Pharmaceuticals Inc ,Ionis Pharmaceuticals Inc ,Exelixis Inc Incyte Corporation ,Blueprint Medicines Corporation ,Company Annual Report On Form ,United Therapeutics Corporation ,Alkermes ,Company Board ,Exchange Commission ,Drug Administration ,Denner ,Innisfree Ma Incorporated ,Alnylam Pharmaceuticals Inc ,Nasdaq ,Alkerme Board Nominees On Company ,Shareholders Vote ,Board Nominees ,Annual Meeting ,Alkermes Board ,Enhancement Plan ,Sarissa Capital Management ,Lead Independent Director ,Value Enhancement Plan ,Grow Alkerme ,Leverage Alkerme ,Final Award ,Peterson Alva ,Alkerme Board ,Private Securities Litigation Reform Act ,Annual Report ,Additional Information ,Alnylam Pharmaceuticals ,Incyte Corporation ,Ionis Pharmaceuticals ,Ironwood Pharmaceuticals ,Neurocrine Biosciences ,Sage Therapeutics ,Sarepta Therapeutics ,United Therapeutics ,Stabile Ertr ,Chart Profi Stefan Klotter ,Blue Chips ,